Drugmakers Novo Nordisk and Eli Lilly are battling it out in the GLP-1 weight loss market. The pill version of Novo Nordisk's ...

There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my ...

There are always investors who want to get rich as quickly as possible. That's why Wall Street has happily created ...

The Direxion Daily Financial Bear 3X Shares is still useful for some traders, but don't expect it to act like 2008 is back.

Bill Ackman turned heads when adding a large position in Meta Platforms ( META +1.66%) to his portfolio. The billionaire ...

Billionaire Stanley Druckenmiller Still Isn't Buying Nvidia. But He Recently Picked Up Shares of This AI Stock That's Among ...

Alphabet has become a leading force in the development of artificial intelligence. CEO Sundar Pichai has ambitious plans for ...

Realty Income (O +0.92%) just expanded into Mexico and secured a $1.5 billion joint venture while maintaining a 5% monthly ...

In the end, this is just the way the pharma industry works, and Novartis is used to navigating these ebbs and flows while rewarding dividend investors well for sticking around. Novartis isn't likely ...

Merck isn't exciting in the same way as GLP-1 leader Eli Lilly. But it presents an opportunity for investors who use ...

Year-to-date in 2026, Amazon is trading down 10%, making it the second-worst-performing Magnificent Seven stock (behind ...

Of those that do, few are capable of sustaining years of payout increases without interruptions. The company's accomplishment ...